Drug Profile
Research programme: drug discovery - Evotec SE/Yale University
Alternative Names: TargetDBR (DNA Break Repair)Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Yale University
- Developer Evotec SE; Yale University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; CNS disorders; Immunological disorders; Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in USA
- 16 Jul 2016 No recent reports of development identified for research development in Immunological-disorders in USA